To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: ICAAC: Gemifloxacin More Effective Than Clarithromycin In Treating Chronic Bronchitis Recurrence URL: http://www.pslgroup.com/dg/1E17BE.htm Doctor's Guide September 18, 2000
HAMILTON, ON -- September 18, 2000 -- An investigational new antibiotic, gemifloxacin mesylate (Factive), produced significant long-term clinical and health economic outcomes compared to clarithromycin in acute exacerbations of chronic bronchitis (AECB). The study, conducted by McMaster University researchers, was presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. The study, Gemifloxacin Long-term Outcomes in Bronchitis Exacerbations (GLOBE), showed that 30 per cent fewer patients treated for five days with gemifloxacin experienced recurrences of chronic bronchitis requiring antibiotic treatment compared to patients treated for seven days with clarithromycin, a commonly-used treatment for the condition. A greater reduction was also seen in related hospitalizations in the gemifloxacin arm of the study compared to the clarithromycin arm. "The GLOBE study presents groundbreaking data confirming that the choice of antibiotic can have an impact on long-term health outcomes and overall patient success rates," said Lionel Mandell, M.D., Professor of Medicine at McMaster University. "Patients enrolled in the GLOBE study exhibited not only less frequent exacerbations of chronic bronchitis with gemifloxacin treatment, but also exhibited reduced hospitalization rates compared to a commonly-used antibiotic for the condition." Thirty per cent fewer gemifloxacin-treated patients in the GLOBE study demonstrated recurrence of AECB requiring antibiotic treatment compared to the clarithromycin group at six months. The proportion of patients whose initial AECB resolved and who had experienced no further recurrences by week 26 was 71.0 per cent (120 out of 169 patients) in the gemifloxacin arm compared with 58.5 per cent (100 out of 171 patients) in the clarithromycin arm. In the study, researchers identified a reduction in RTI-related hospitalization during a six-month period following the start of gemifloxacin therapy compared to clarithromycin. The number of patients hospitalized for AECB following start of therapy was 2.3 per cent for the gemifloxacin arm of the study and 6.3 per cent for the clarithromycin arm. "It's important to have strong evidence to support the use of new highly active treatments," said Dr. Mandell. "The antibiotic studied in GLOBE, gemifloxacin, offers physicians a powerful new therapy for respiratory infections, which is particularly important as bacterial resistance continues to grow worldwide." The double-blind phase III study was conducted over a six-month period and involved 438 patients (214 were treated with 320mg of gemifloxacin once daily for five days and 224 were treated with 500 mg of clarithomycin twice daily for seven days). Participants in both groups had similar histories of systemic steroid use, smoking and acute exacerbations of bronchitits. The study assessed clinical status and use of health care resources. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.